Preparing for the 2022 EU In Vitro Diagnostic Regulation (IVDR): Linguistic & Labeling Readiness
Ahead of the May 2022 application date of Regulation (EU) 2017/746 (IVDR) and the progressive rollout rules announced in late 2021, diagnostic manufacturers must overhaul their multilingual IFU and performance evaluation workflows.
From Self-Certification to Notified Body Scrutiny Under EU IVDR
Under the legacy In Vitro Diagnostic Directive (98/79/EC), roughly 80% of IVD devices—ranging from clinical chemistry analyzers to infectious disease assays—were self-certified by manufacturers without Notified Body intervention. Under Regulation (EU) 2017/746 (IVDR), which applies from May 26, 2022 (with phased transitional periods for existing legacy devices proposed by the European Commission in late 2021), a new risk-based classification system (Classes A, B, C, and D) shifts nearly 80% of IVDs under direct Notified Body oversight. Consequently, translated Instructions for Use (IFUs), labels, and Performance Evaluation Reports form an integral part of the regulated technical documentation.
Self-Testing Diagnostics and Layperson Readability
For self-testing and near-patient diagnostic devices, IVDR mandates that all instructions, warnings, and result interpretations be translated into the official language(s) of the Member State where the test reaches the user, written in clear, unmistakable terminology understandable to laypersons. Partnering with ISO 13485 and ISO 17100 certified language providers ensures terminology consistency across assay packaging, software interfaces, and EUDAMED registrations.
Executive Takeaways for Global Enterprises
- Key Insight: EU IVDR (Regulation 2017/746) introduces a four-tier risk classification (Class A to Class D), dramatically expanding Notified Body review of translated IFUs.
- Key Insight: Self-testing diagnostic instructions must be localized for layperson comprehension across all target EU Member State languages.
- Key Insight: Centralized terminology databases aligned with EDMA and MedDRA standards streamline multi-country regulatory submissions.
Benötigen Sie zertifizierte mehrsprachige Übersetzungen, beglaubigte Fachübersetzungen oder ISO-konforme Lokalisierung für Ihre internationalen Projekte? Fordern Sie ein kostenloses individuelles Angebot von Alphatrad an und erhalten Sie innerhalb von 24 Stunden eine detaillierte Rückmeldung.
Editorial & Copyright Attribution Note: This industry analysis has been independently synthesized and adapted by Alphatrad’s editorial team based on verified regulatory documentation and industry research originally published by European Commission – Medical Devices & IVDR. For the original publication and primary documentation, please consult:
Source: https://health.ec.europa.eu/medical-devices-sector/new-regulations_en
Hinterlassen Sie einen Kommentar
Wollen Sie an der Diskussion teilnehmen?Wir freuen uns über ihren Beitrag!